Topiramate Impurities and Topiramate
Daicel Pharma is a trusted provider of quality Topiramate impurity standards, including Topiramate EP Impurity A, Topiramate EP Impurity B, and Topiramate EP Impurity D. They are crucial in meticulously evaluating the quality, stability, and safety of the active pharmaceutical ingredient, Topiramate. Furthermore, Daicel Pharma specializes in the custom synthesis of Topiramate impurities, guaranteeing that individual client specifications are met with precision. With global shipping capabilities, these impurities can be conveniently delivered to customers worldwide, offering unparalleled convenience.
Topiramate [CAS: 97240-79-4] is an anti-epileptic drug to manage seizures and prevent migraines. It treats patients with partial-onset seizures, tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.
Topiramate: Use and Commercial Availability
Topiramate is a hexose derivative, belongs to the class of second-generation anti-epileptic drugs, and is for managing and treating epilepsy and migraines. It helps suppress abnormal electrical activity in the brain and to restore the natural equilibrium of nerve function.
Topiramate is available under Eprontia, Qudexy XR, Topamax, Topamax Sprinkle, and Trokendi XR.
Topiramate Structure and Mechanism of Action
The chemical name of Topiramate is 2,3:4,5-bis-O-(1-methylethylidene)- β-D-Fructopyranose 1-sulfamate. Its chemical formula is C12H21NO8S, and its molecular weight is approximately 339.36 g/mol.
Topiramate blocks voltage-dependent sodium channels and is an anti-epileptic for preventing migraine.
Topiramate Impurities and Synthesis
Topiramate impurities can arise during synthesis1 due to storage or using specific raw materials and intermediates in manufacturing. These impurities encompass related compounds, degradation products, and process impurities. Stringent quality control measures and analytical methods are crucial to ensure the purity and safety of Topiramate for patient use.
Daicel provides a comprehensive Certificate of Analysis (CoA) for Topiramate impurity standards such as Topiramate EP Impurity A, Topiramate EP Impurity B, and Topiramate EP Impurity D. The CoA includes detailed characterization data such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. Additionally, upon delivery, a complete 13C-DEPT is also provided. Daicel possesses the technology and expertise to synthesize any unknown Topiramate impurity or degradation product.
- Maryanoff, Bruce E.; Gardocki, Joseph F., Anticonvulsant sulfamate derivatives, McNeilab, Inc., United States, US4513006A, April 23, 1985
- Micheel, A. P.; Ko, C. Y.; Evans, C. R., Assay of residual organic solvents in topiramate drug substance by capillary gas chromatography, Journal of Pharmaceutical and Biomedical Analysis, Volume: 11, Issue: 11-12, Pages: 1233-8, 1993
Frequently Asked Questions
Impurities in Topiramate can contribute to its degradation or instability under specific storage conditions. Therefore, proper storage conditions, including temperature, light exposure, and moisture control, are essential to maintain the stability and quality of the drug over its shelf life.
Toxicity testing is conducted on impurities found in Topiramate to evaluate their potential adverse effects. These tests play a crucial role in determining the safety profile of these impurities and establishing appropriate limits to safeguard the well-being of patients.
Throughout the commercial production of Topiramate, stringent quality control measures help regulate the levels of impurities. Batch testing, validation of preparation processes, and adherence to regulatory guidelines help guarantee the drug's consistent quality and safety.
Methanol is a common solvent used when analyzing many impurities in Topiramate.
The recommendation is to store Topiramate impurities at room temperature, within 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.